These findings reveal the importance of CD4+ T cell heterogeneity in the bladder tumor environment, and underscores that cancer immunotherapies may elicit both quantitative enrichment and focusing of the antigenic repertoire of novel intratumoral cytotoxic CD4+ populations in lieu of effects on cytotoxic CD8+ cells. This evidence concerns the gene CD4 and urinary bladder neoplasm.